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Objectives: Regulatory policies, including economic incentivization through pat-
ent extensions, have been implemented to stimulate pediatric research, however 
disparity exists for the neonatal subpopulation. This analysis was conducted to 
identify the availability of neonate-specific data for frequently used medications in 
Neonatal Intensive Care Units (NICUs) and to determine the extent to which pedi-
atric exclusivity has increased information for drugs used in neonates. MethOds: 
A search was conducted utilizing the FDALabels database to identify all FDA-
approved NDA, BLA and ANDAs from 01/01/1980 to 08/01/2013 searching for the 
terms “neonate”, “newborn” and “infant” present in any of the following label sec-
tions; “Indication and Usage”, “Dosage and Administration” and “Pediatric Use”. 
The results were cross-referenced with a recently published list of 100 frequently 
prescribed drugs in NICUs and drugs granted pediatric exclusivity by the FDA as 
of August, 2013. Results: A total of 737 unique labels for 110 distinct drugs were 
identified (including 18 combination products and 15 modified versions of previ-
ously marketed drugs). “Newborn” was identified in 450 labels; “infant” in 414 labels 
and “neonate” in 167 labels. More than one search term was found in 294 labels. Only 
19% of drugs frequently used in NICUs mentioned neonates, newborns or infants on 
their labels. Mention of neonates, newborns or infants occurred in 4.5% (n= 9) of the 
drugs with pediatric exclusivity; while 8.7% (n= 17) of drugs granted pediatric exclu-
sivity were used frequently in the NICU. Only two drugs frequently used in NICUs 
mentioned neonate, newborn or infant on their label and had pediatric exclusiv-
ity. cOnclusiOns: Despite regulatory incentives, a paucity of neonatal data exist 
for drugs frequently used in NICUs. Our data suggest that pediatric exclusivity did 
not yield sufficient neonatal data.
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ImPact Of tHe PatIent PrOtectIOn and affOrdable care act 
cOntracePtIve cOverage mandate On UtIlIzatIOn Of refIllable and 
lOng-actIng reversIble cOntracePtIves
Vlahiotis A1, Tian Y1, Iyengar R2
1Express Scripts, St. Louis, MO, USA, 2Express Scripts Holding Company, St. Louis, MO, USA
Objectives: One provision of the Patient Protection and Affordable Care Act (PPACA) 
requires that most insurers make prescription contraceptives—including refillable 
and long-acting reversible contraceptive methods (LARCs)—available at no out-
of-pocket cost to beneficiaries. The objective of this study was to determine if the 
implementation of the mandate increased contraceptive utilization. MethOds: 
We conducted a retrospective analysis using integrated pharmacy and medical 
claims for three cohorts of commercially-insured females aged 15 to 49. Each cohort 
(n= 360143, n= 352,169, and n= 391,138) was continuously enrolled for 12-month 
periods, respectively. “Pre-PPACA-Period 1” (January 1, 2011 to June 30, 2011) con-
sidered cost and utilization two years prior to PPACA. “Pre-PPACA-Period 2” (January 
1, 2012 to June 30, 2012) looked at the year prior to PPACA implementation, and the 
“Post-PPACA Period” (January 1, 2013 to June 30, 2013) captured the early experience 
immediately after implementation of the coverage mandate. Two pre-PPACA-periods 
allowed for better understanding of underlying secular trends occurring prior to 
the mandate. The incidence of new refillable and LARC methods, discontinuation 
and switching patterns and cost were measured across each time period. Results: 
The incidence of refillable contraceptive use increased minimally: from 3.45% in 
the first half of 2011 to 3.59% in the first half of 2012, and to 3.72% in the first half 
of 2013. The incidence of LARC use increased substantially (44.4% from 0.50% to 
0.65% between the first half of 2011 and the first half of 2013). The initiation rate 
of LARCs was significantly higher after the mandate compared to previous periods 
(OR= 1.45, 95% CI = 1.36-1.54), possibly due to increased switching from refillable to 
LARC methods. cOnclusiOns: We found little evidence that the PPACA contracep-
tive coverage mandate rule has yet resulted in meaningful increases in refillable 
contraceptive use, but it was associated with an increase in the initiation of LARCs.
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tHe ratIOnale Of early PrescrIPtIOn Of antIbIOtIcs In 
OrganOPHOsPHOrUs POIsOnIng PatIents
Priyendu A1, Nagappa AN2, Varma M1, K E V1, Prabhu NN3, Rahim AA3
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Objectives: To study the rationale of early prescription of antibiotics in case of 
patients with Organophosphorus poisoning. MethOds: In this study patients 
admitted to the ICU due to organophosphorus poisoning during a six-month 
period were included. Patients were grouped into group-A and group-B on the 
basis of antibiotics prescribed and not prescribed respectively.  The prescription of 
antibiotics was classified as prophylactic, empirical and definitive depending on 
the time of prescription. The effect of antibiotic prescription on the length of stay, 
cost and clinical outcome was observed. The cost of treatment was obtained from 
the finance department of the hospital. The length of stay and cost of treatment 
for the two groups were compared using the non-parametric Mann-Whitney U 
test. Results: There were 54 patients categorized in three groups according to the 
severity of poisoning as mild (22%), moderate (48%) and severe (30%). Antibiotics 
were prescribed for 74.07% of the patients. Prophylactic antibiotics were prescribed 
in 53.7% cases. The median cost of treatment for group-A patients was INR 60,216 
and for group-B patients was INR 27,225 (p= 0.001). The median length of stay 
for group-A and group-B was 14 days and 10 days respectively (p= 0.011). The 
median cost of treatment for moderately poisoned patients prescribed with pro-
phylactic antibiotics was INR 74595.6 as compared to INR 30,902 for moderately 
poisoned patients of group-B (p< 0.05). cOnclusiOns: Early prescription of anti-
biotics without any evidence of infection in case of organophosphorus poisoning 
patients showed a higher cost of treatment and inferior outcomes as compared 
to OPP cases where a prophylactic antibiotic was not prescribed. The use of higher 
antibiotics in these cases also lead to increase in antibiotic resistance. There is a 
need to revise the antibiotic prescription guidelines in case of Organophosphorus 
poisoning patients.
PIH59
Prevalence and determInants Of Use Of POtentIally InaPPrOPrIate 
medIcatIOns In elderly InPatIents: stOP and start crIterIa
Boya C, Goud T, Spurthy R, Kathhon R, Ravindra R
CES college of pharmacy, kurnool, India
Objectives: Use of potentially inappropriate medications (PIMs) among the elderly 
is a serious public health problem because it is intrinsically linked to increased 
morbidity and mortality, causing the high costs to public health systems. Objectives 
of this study were to determine the prevalence and predictors of PIM prescribing 
in elderly inpatients using STOP and START criteria MethOds: The prospective 
observational study was carried at a private tertiary care hospital. Prescriptions 
of elderly inpatients aged 60 years and above were collected and analyzed. PIMs 
were identified with the help of STOP and START criteria. Predictors associated 
with use of PIMs were identified by bivariate and multivariate logistic regression 
analysis. Results: The results were based on data of 60 patients. More than half 
(56%) were males and 50% were aged between 60–69 years with a mean average 
age of 69 years. Mean number of diagnoses and medications were two and nine, 
respectively. A total of 18 (30%) patients were prescribed with at least 1 PIM according 
STOP Criteria. Most commonly prescribed PIMs were systemic corticosteroids (29%) 
followed by theophyline (18%) and betablockers (10%). On multivariate regression, 
important predictors for PIM prescribing were found to polypharmacy, number of 
diagnoses. cOnclusiOns: The results show that PIMs prescribing is high in Indian 
elderly inpatients STOP and START criteria, it is more effective in identifying the 
PIMs. This study is ongoing and we will present the data upto 250 patents before 
the presentation.
PIH60
evalUatIng fractUre-related exPenses and HealtH care resOUrce 
UtIlIzatIOn amOng POst-menOPaUsal wOmen In tHe U.s. medIcaId 
POPUlatIOn
Xie L1, Keshishian A1, Wang Y1, Baser O2
1STATinMED Research, Ann Arbor, MI, USA, 2STATinMED Research, The University of Michigan, 
MEF University, Ann Arbor, MI, USA
Objectives: To evaluate fracture-related expenses and health care resource utiliza-
tion among post-menopausal women in the U.S. Medicaid population. MethOds: 
Female patients diagnosed with fractures (International Classification of Disease, 
9th Revision, Clinical Modification [ICD-9-CM] codes: 733.12-.16, 805.0, 805.2, 805.4, 
805.6, 805.8, 808.0, 808.4, 808.8, 810.0, 812.0, 812.2, 812.4, 813.0, 813.2, 813.4, 813.8, 
814.0, 820.0, 820.2, 820.8, 821.0, 821.2, 823.0, 823.2, 823.4, 823.8) were identified using 
U.S. Medicaid data from 01JAN2009 through 31DEC2009. The initial diagnosis date 
was designated as the index date. A control cohort that included patients without 
fractures of the same age, race, region and baseline Charlson Comorbidity Index 
score was created. The index date for the control cohort was randomly assigned to 
minimize selection bias. Patients in both cohorts were required to be age ≥ 50 years, 
with continuous medical and pharmacy benefits for 1-year pre- and post-index date. 
Propensity score matching (PSM) was used to compare health care costs and utiliza-
tions during the follow-up period. Results: Before matching (n= 80,516), fracture 
patients were more likely to be white (71.2% vs. 46.2%), reside in the South U.S. region 
(39.2% vs. 34.1%) and have chronic obstructive pulmonary disease (26.7% vs. 21.3%). 
After 1:1 PSM, a total of 22,089 patients with proportionate baseline characteristics 
were matched from each cohort. Patients in the fracture cohort had higher propor-
tions of inpatient stays (31.0% vs. 8.1%, p< 0.0001), emergency room (ER; 47.0% vs. 
15.4%, p< 0.0001), physician office (73.6% vs. 47.3%, p< 0.0001) and outpatient visits 
(98.9% vs. 71.6%, p< 0.0001). Higher health care resource utilizations translated to 
higher costs for post-menopausal fracture patients than for controls, including long-
term care ($9,191 vs. $7,212, p< 0.0001), physician office visit ($428 vs. $293, p< 0.0001) 
and total costs ($17,698 vs. $13,032, p< 0.0001). cOnclusiOns: Post-menopausal 
women with fractures had significant health care resource utilization and expenses 
compared to those without fractures.
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Objectives: To assess the relationship between DGIR and HRU in elderly patients 
to evaluate potential benefit from pharmacogenetic testing. MethOds: A ret-
rospective cohort of patients age ≥ 65 years was identified through Inovalon’s 
MORE2® registry with continuous enrollment, taking ≥ 3 prescription medications 
(July 1, 2012 - March 31, 2013) and on ≥ 1 drug metabolized by a polymorphic drug 
metabolizing enzyme. Patients were stratified into zero, low, medium, and high 
DGIR groups via a diagnostic test (Genelex Youscript®). Counts of HRU during 9 
months follow-up post index-date (date of first claim for ≥ 1 drugs with pharma-
cogenetic implications) included all-cause hospitalizations, emergency-room and 
clinic visits. Poisson regression was used to test the association between DGIR and 
HRU counts. The model was adjusted for age, gender, race, Charlson Comorbidity 
Index (CCI) and number of known drug-drug interactions. Results: A total of 
252,184 patients were included and the mean age was 74 ± 6 and 60% were female. 
The median DGIR score was 8.7% [IQR 2.3%-44%]. There were 59,559 (23.6%) with 
a DGIR score of zero, 82,224 (32.6%) with low risk (0-20%), 33,439 (13.3%) with 
medium risk (20-40%), and 76,962 (30.5%) with high risk (> 40%). Regression analy-
sis revealed that the low and medium DGIR groups were associated with a 9% 
(95%CI 8.4 to 9.7%, p < 0.0001), and 8% (95%CI 7.7 to 9.2%, p < 0.0001) increase 
in the rate of HRU, compared to zero risk. The high DGIR group was associated 
with a 5% (95%CI 4.2 to 5.3%, p < 0.0001) decrease in HRU, compared to zero-
risk. cOnclusiOns: Among elderly patients, low and medium DGIR groups were 
associated with increased rates of HRU. In contrast, high DGIR was associated with 
lower HRU rates. This may be explained by a time-dependent effect of changing 
DGIR as a result of medication changes over time.
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measUrIng sPendIng trends fOr tHOse wItH emPlOyer-sPOnsOred 
InsUrance UsIng admInIstratIve data
Marder WD1, Moldwin E2, Pickens GT2
1Truven Health Analytics, Cambridge, MA, USA, 2Truven Health Analytics, Chicago, MA, USA
Objectives: There is limited timely information about healthcare spending in 
the US for those people under 65 with employer-sponsored insurance. This study 
explores the methods needed to use a large administrative database to fill this 
need. The fully implemented methodology will be used to portray recent trends 
in overall spending and highlight the role of prescription drugs in the context of 
those trends. MethOds: The Truven Health MarketScan database is updated each 
calendar quarter. This convenience sample is weighted to reflect the age, sex, and 
location characteristics of the US population with employer-sponsored insurance 
as captured by the US Medical Expenditure Panel Survey. Recent quarterly spending 
is adjusted for incurred but not yet reported services using a combination of cor-
rection factors and time series analysis. Spending is classified either by setting or 
by provider type. Overall and subpopulation breakdowns are presented. Results: 
Per capita annual spending has seen a compound annual growth rate of 5.2% over 
the period of 2003–2013. While the 0–17 age group has seen the highest annual 
growth rate at 6.5% (from $1,476 in 2003 to $2,772 in 2013), the 45–64 age group 
continues to have a higher level of expenditure ($8,175) despite a lower annual 
growth rate of 4.1%. Outpatient spending grew faster (6.0%) than either inpatient 
(4.5%) or prescription drug (4.0%). In the most recent year there has been an uptick 
in prescription drug spending fueled almost entirely by new treatments for Hepatitis 
C. cOnclusiOns: It is possible to create a useful, timely index of spending for 
the under 65 population of the US with employer-sponsored insurance. Recent 
trends indicate a growth in spending for children and a recently revived growth 
for prescription drugs.
PIH63
temPOral trend In Use Of Permanent female sterIlIzatIOn 
PrOcedUres and cHaracterIstIcs Of wOmen wHO UndergO tHem In a 
cOmmercIally-InsUred POPUlatIOn In tHe U.s
Carney P1, Lin J2, Xia F3, Law A1
1Bayer HealthCare Pharmaceuticals, Whippany, NJ, USA, 2Novosys Health, Green Brook, NJ, USA, 
3Bayer Healthcare Pharmaceuticals, Whippany, NJ, USA
Objectives: Literature is lacking on the temporal pattern of use of permanent steri-
lization procedures and the characteristics of women who undergo them. This study 
evaluated the temporal pattern of use of hysteroscopic sterilization (HS) vs. inter-
val laparoscopic bilateral tubal ligation (LBTL) and differences in characteristics of 
women who undergo permanent sterilization procedures. MethOds: Women aged 
15-49 years who had a claim for HS or LBTL procedures during 1/1/2003-12/31/2012 
were identified from the Truven Health MarketScan Commercial Claims and 
Encounters database. The proportions and characteristics of women who underwent 
HS and LBTL were determined for the study population and subgroups stratified 
by year of procedure. Logistic regressions were used to identify predictors of use of 
HS vs. LBTL. Results: Among the study population, 32,012 had HS and 64,725 had 
LBTL. Women who had HS vs. LBTL were slightly older (37.2 vs. 36.4 years, p< 0.0001), 
but had similar Charlson Comorbidity Index scores. The proportion of women who 
had HS increased from 7% in 2005 to 45% in 2012. Compared to women who had 
a sterilization procedure between 2003 and 2007, women who had one between 
2008 and 2012 were more likely to undergo HS (Odds Ratio (OR): 7.1, p< 0.0001). 
Obesity was associated with a greater likelihood of having HS vs. LBTL (OR: 1.08, 
p= 0.03). Additionally, slightly greater age (OR: 1.03, p< 0.0001), having had a prior 
pregnancy/delivery (OR: 1.38, p< 0.0001), and having had prior oral contraceptive use 
(OR: 1.53, p< 0.0001) were associated with greater likelihoods of having had HS than 
LBTL. cOnclusiOns: Using a large claims database analysis, we observed among 
commercially-insured women that the likelihood of having HS vs. LBTL increased 
approximately 7-fold in years 2008-2012 from in years 2003-2007. Older age, prior 
pregnancy/delivery, and prior oral contraceptive use were associated with a greater 
likelihood of having HS vs. LBTL.
PIH64
gender dIsParItIes In mIgraIne PHarmacOtHeraPy: aPPlIcatIOn Of 
PrOPensIty scOre-matcHed analyses
Lai L1, Sanabria S2
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Objectives: Migraine is a debilitating chronic disease that affects approximately 
13% of the United States population. Gender differences in migraine treatment have 
been studied; however, the results are often overlooked due to lack of controlling 
for selection bias. The study aimed to investigate gender differences in migraine 
treatment, using propensity score-matched analyses. MethOds: A retrospective 
population-based study was conducted by analyzing a national database from 2010 
National Ambulatory Medical Care Survey. All patient visits with a diagnosis of 
migraine were included. A series of weighted descriptive analyses were used to 
estimate the prevalence of medications recommended in the American Neurology 
Association practice guidelines. Multivariate logistic regression and Greedy 8 to 1 
digit match were used to create propensity scores. A propensity score weighted 
logistic regression model was fitted to compare the gender difference on migraine 
treatment while controlling for age, race, pay type, and physician specialty. All analy-
ses utilized SAS PROCSURVEY applications and incorporated sample weights and 
standard errors. Results: Among 5.45 million outpatient visits that took place in 
2010 with migraine diagnosis, female accounted for nearly four-times than male 
(79.8% vs. 20.2%). Of these, 3.08 million visits (56.48%) received at least one abortive 
or prophylactic migraine prescription. Prior to propensity-score matching, the socio-
economic characteristics of the two cohorts (with vs. without migraine pharmaco-
therapy) were significantly different (P< 0.001). After matching, there was no longer 
a significant difference between two cohorts (P> 0.05). Female received significant 
more migraine treatment than male (OR: 3.2, 95% CI: 1.137-8.932). cOnclusiOns: 
The assessment of gender differences in health care is challenging because of the 
potential biases that require careful adjustment. This study successfully reduced 
selection bias by propensity score-matched methodology and concluded significant 
gender disparity in migraine pharmacotherapy. This study also provides an empiri-
cal evident of undertreated migraine conditions in the US.
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treatment Patterns Of wOmen dIagnOsed wItH UterIne fIbrOIds 5 
years Pre and POst dIagnOsIs: a lOngItUdInal retrOsPectIve claIms 
analysIs Of a cOmmercIally InsUred POPUlatIOn In tHe Us
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Objectives: To evaluate treatment patterns among women with uterine fibroid (UF) 
versus matched controls for 5 years before and after diagnosis. MethOds: Women 
with a UF diagnosis (International Classification of Diseases 218.xx) aged 18-45 years 
were identified in Truven Health MarketScan® 2000-2010 data, and matched 1:1 to 
women without UF (control) by age, region, and insurance type. The first recorded 
UF diagnosis date was assigned as the index date for the UF patient and matched 
control. Continuous eligibility in a health plan for ≥ 1 year pre- and post-index was 
required. UF-related medications and surgical treatments during the five pre- and 
post-index years were evaluated annually, and compared between UF patients and 
controls using McNemar’s tests. Results: A total of 84,954 matched pairs, with a 
mean age of 39.3 years at the index date were included in the analysis. During the 
3 years prior to the index date, annual medication use (ranging from 18.7-19.5% 
vs. 16.5-18.4% for combined oral contraceptives and 0.4-0.9% vs. 0.2-0.3% for GnRH 
agonists) and UF-related surgery use (0.8-0.9% vs. 0.1-0.4% for endometrial abla-
tions), respectively, was significantly higher among UF patients than controls (all p 
values < 0.05). In the first year post-index, a greater proportion of UF patients than 
controls were treated with medications (combined oral contraceptives, 17.1% vs. 
15.6%; progestins, 10.7% vs. 4.9%; and GnRH agonists, 2.8% vs. 0.2%) and surgeries 
(hysterectomies, 27.9% vs. 0.5%; endometrial ablations, 6.3% vs. 0.6%; myomecto-
mies, 5.9% vs. < < 0.1%), respectively (all p values < 0.05). In the next four years of 
follow-up, the annual utilization difference decreased, but remained higher in UF 
patients and the differences were significant for GnRH agonist, hysterectomy, and 
myomectomy use. cOnclusiOns: Patients with UF used significantly more UF 
treatments than controls after diagnosis, and also during the period before diag-
nosis. Treatment usage peaked in the first year post-diagnosis.
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HealtHcare UtIlIzatIOn and cOsts Of serOtOnIn syndrOme wItH 
cOncOmItant Use Of serOtOnergIc agents
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Objectives: Serotonin syndrome (SS) is an adverse drug reaction that may occur 
in patients receiving monotherapy or combinations of serotonergic agents (SAs). 
This study examined healthcare utilization and costs of SS in two different popu-
lations. MethOds: Adult (age ≥ 18 years) patients prescribed SAs were identified 
using the Veterans Health Administration (VHA) dataset (01OCT2008-30SEPT2012) and 
the IMS PharMetrics Plus dataset (01JAN2010-31DEC2013). Patients with continuous 
health plan enrollment 12 months pre-index date, defined as the first SA prescrip-
tion claim date, were included and observed until death, disenrollment or the end of 
the study period. Patients were assigned to cohorts based on drug exposure: single 
monoamine oxidase inhibitor (MAOI) drug, MAOI drugs in combination with other 
SAs, single non-MAOI SA, and multiple non-MAOI SAs (2, 3, 4, and ≥ 5 SAs). Outcomes 
of interest were annual incidences of SS event (ICD-9-CM: 333.99) and associated 
health care utilization and costs. Results: The incidence rate of SS was similar 
between veterans (VHA) and commercially insured patients (IMS) prescribed SAs and 
decreased over time (IMS: 0.17% in 2010 to 0.09% in 2013; VHA: 0.19% in 2009 to 0.07% 
in 2012). 0.88% and 4.35% of all SS events led to hospitalization in the IMS and VHA 
populations, respectively. Proportion of IMS patients with SS-related hospitalization 
increased as the number of non-MAOI SAs increased (0.24% for one drug vs. 6.93% for 
≥ 5 drugs). Average healthcare cost per SS event was higher in the MAOI combination 
cohort (IMS: $2,474; VHA: $2,896) and the ≥ 5 non-MAOI SAs cohort (IMS: $1,167; VHA: 
$3,837) than the single non-MAOI SA cohort. cOnclusiOns: The overall incidence 
of SS and proportion of serious SS leading to hospitalization are similar in the VHA 
and IMS populations. Use of MAOIs or multiple SAs concomitantly increases the risk 
of SS and leads to higher health care utilization and costs.
PmH2
antIcHOlInergIc medIcatIOn Use and rIsk Of IncIdent fractUres In 
tHe elderly wItH dePressIOn
Chatterjee S.1, Aparasu R.1, Carnahan R.2, Chen H.1, Johnson M.L.1
1University of Houston, Houston, TX, USA, 2University of Iowa College of Public Health,, Iowa, 
IA, USA
Objectives: There is limited evidence regarding the role of anticholinergic medica-
tions in falls/fractures among the elderly. This study examined the risk of fractures 
associated with anticholinergic use in elderly nursing home residents with depres-
sion. MethOds: A population-based nested case control study was conducted 
using 2007-2010 Minimum Data Set (MDS)-linked Medicare data from all states. 
Patients with continuous coverage in Medicare Parts A, B, D and no HMO coverage 
during the study period or until death were considered. The base cohort included 
